Currently, HER2-low breast cancer is defined as tumors with an immunohistochemical (IHC) score of 1+ or 2+ and negative in situ hybridization (ISH) results, accounting for approximately 45%-55% of all breast cancers (3, 4). This evidence concerns the gene ERBB2 and breast cancer.